Analyst Ratings For Adverum Biotechnologies Inc (NASDAQ:ADVM)
Today, Cowen reiterated its Buy rating on Adverum Biotechnologies Inc (NASDAQ:ADVM).
There are 4 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Adverum Biotechnologies Inc (NASDAQ:ADVM) is Hold with a consensus target price of $7.8750 per share, a potential 47.15% downside.
Some recent analyst ratings include
- 7/9/2019-Adverum Biotechnologies Inc (NASDAQ:ADVM) had its Buy rating reiterated by Cowen
- 6/13/2019-Adverum Biotechnologies Inc (NASDAQ:ADVM) has coverage initiated with a Mkt Perform ➝ Market Perform rating
- 11/4/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) gets downgraded to Hold by Cantor Fitzgerald with a price target of $4.00
- 11/2/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) had its Hold rating reiterated by Chardan Capital with a $4.50 price target
- 11/2/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) gets downgraded to Hold by SunTrust Banks
- On 5/6/2019 James Paul Scopa, Director, bought 20,000 with an average share price of $6.71 per share and the total transaction amounting to $134,200.00.
- On 6/8/2015 Mehdi Gasmi, VP, sold 500 with an average share price of $38.64 per share and the total transaction amounting to $19,320.00.
- On 6/8/2015 Paul Wachter, Director, sold 1,192 with an average share price of $38.64 per share and the total transaction amounting to $46,058.88.
- On 5/26/2015 Paul Wachter, Director, sold 1,192 with an average share price of $36.94 per share and the total transaction amounting to $44,032.48.
- On 5/22/2015 Steven Daniel Schwartz, Director, sold 16,875 with an average share price of $38.38 per share and the total transaction amounting to $647,662.50.
- On 5/13/2015 Linda Bain, CFO, sold 285 with an average share price of $34.94 per share and the total transaction amounting to $9,957.90.
- On 5/13/2015 Mark S Blumenkranz, Director, sold 715 with an average share price of $34.94 per share and the total transaction amounting to $24,982.10.
About Adverum Biotechnologies Inc (NASDAQ:ADVM)
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. Read More…
Recent Trading Activity for Adverum Biotechnologies Inc (NASDAQ:ADVM)
Shares of Adverum Biotechnologies Inc closed the previous trading session at 14.90 up +2.74 22.53% with 14.96 shares trading hands.